Cardiovascular Engineering Overview

Principles

Definition

Cardiovascular engineering is an interdisciplinary field that applies engineering principles and methodologies to study, analyze, and manipulate the structure, function, and mechanics of the cardiovascular system. It aims to develop innovative technologies, devices, and therapeutic strategies for the diagnosis, treatment, and prevention of cardiovascular diseases, thereby improving patient outcomes.

Ontological type

Device Technologies

Clinical Applications

Core Methods

Key developments

Key Figures

Perfusion Bioreactor Era era

Róbert Langer [1] is affiliated with the Harvard–MIT Division of Health Sciences and Technology [3] and Harvard University [4], and his work includes perfusion-improved tissue architecture [6], Accordion-like honeycombs for tissue engineering of cardiac anisotropy [5], and a mathematical model of oxygen distribution in engineered cardiac tissue [7]. Róbert Langer [1] advanced these themes by illustrating how perfusion-improved tissue architecture [6], Accordion-like honeycombs for cardiac anisotropy [5], and the mathematical model of oxygen distribution in engineered cardiac tissue [7] support nutrient delivery, cell viability, and maturation of thick constructs, helping drive viability and vascularization in this era. Lisa E. Freed [2] is affiliated with the Harvard–MIT Division of Health Sciences and Technology [3] and Harvard University [4] during this era, and her work includes accordion-like honeycombs for tissue engineering of cardiac anisotropy [5] and Perfusion Improves Tissue Architecture of Engineered Cardiac Muscle [6]. Lisa E. Freed [2] advanced Perfusion Improves Tissue Architecture of Engineered Cardiac Muscle [6] and Accordion-like honeycombs for tissue engineering of cardiac anisotropy [5], demonstrating how architected scaffolds and perfusion drive anisotropic maturation and reduce central necrosis, thereby enabling thicker, clinically relevant cardiac constructs in this era.

In Situ Biofabrication Era era

Simon P. Hoerstrup [1] is a leading cardiovascular engineer whose work spanned Harvard University [3] and ETH Zurich [4]. His key contributions include in situ heart valve tissue engineering with a bioresorbable elastomeric implant [6] and JetValve: rapid manufacturing of biohybrid scaffolds for biomimetic heart valve replacement [7], advancing host-driven regeneration and scalable valve fabrication. Carlijn V. C. Bouten [2] is a prominent figure at Harvard University [3] and the Weizmann Institute of Science [5], where she contributed to in situ heart valve engineering. Her contribution is exemplified by the 2017 in situ heart valve tissue engineering study [6], illustrating how bioresorbable elastomeric implants can guide endogenous regeneration and foster functional integration.